

Supporting Information

MOF-Based Pd Catalyst: A Controllable and Efficient Platform towards Cyclization Reactions of Isonitriles

*Yujie Xia,^a Jiawei Li,^b Meng Li,^a Yanwei Ren,^a Huanfeng Jiang,^a and Wanqing Wu^{*a}*

^[a] School of Chemistry and Chemical Engineering, State Key Laboratory of Luminescent Materials and Devices, South China University of Technology, Guangzhou 510640, China.

^[b] College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, People's Republic of China.

Table of Contents

1. General Information	S2
2. Material Preparation	S2
3. Characterization of Catalysts	S4
4. Characterization Data for All Products	S12
5. Reference	S22
6. Copies of ¹H, ¹³C and ¹⁹F NMR Spectra	S23

1. General Information

Powder X-ray diffraction (PXRD) patterns were collected on a Bruker D8 powder diffractometer at 40 kV, 40 mA with Cu K α radiation ($\lambda = 1.5406 \text{ \AA}$), with a scan speed of 17.7 s/step and a step size of 0.01995 $^\circ$ (2θ). The content of Pd was determined by the inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 5100). The X-ray photoelectron spectroscopy (XPS) experiments were conducted using Thermo fisher Scientific with an Al K α radiation source. SEM images and energy dispersive X-ray spectra (EDS) were collected on MERLIN Compact. Transmission electron microscopy (TEM) and EDS mapping were obtained *via* FEI Tecnai G2 F20. Thermogravimetric analyses (TGA) were performed on a TG209F1 instrument under a flow of N $_2$ at a heating rate of 10 $^\circ\text{C}/\text{min}$. ^1H , ^{13}C and ^{19}F NMR spectra were recorded at a Bruker Model AM-400 (400 MHz) spectrometer 400 MHz NMR spectrometer using CDCl $_3$ as solvent and TMS as an internal standard. Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). The concentration of Pd $^{2+}$ in the reaction solution was detected by flame atom absorption (Z-2300). IR experiments were conducted with Bruker Tensor 27 on either potassium bromide pellets or liquid films between two potassium bromide pellets. GC-MS data were obtained using Trace 1300.

2. Material Preparation

(1) Synthesis of UiO-67-bpy. The UiO-67-bpy was synthesized through solvothermal route as reported.¹ Firstly, ZrCl $_4$ (121 mg, 0.52 mmol) and 2,2'-bipyridine-5,5'-dicarboxylic acid (H $_2$ bpydc, 127 mg, 0.52 mmol) were dissolved in 20 mL of *N,N*-dimethylformamide (DMF). Then, the benzoic acid (1.88 g, 15.6 mmol) was added acting as a modulator to the mixture, which was further dispersed uniformly *via* sonication. Next, the mixture was transferred into a 20 mL Teflon-lined stainless-steel autoclave and heated to 120 $^\circ\text{C}$ for 24 h. The white precipitate was obtained by

centrifugation and washed with DMF (3×10 mL), followed by soaking in acetone for 3 d and exchanging with fresh acetone every day. Finally, the UiO-67-bpy was collected and dried under vacuum at 60 °C for one day.

(2) Synthesis of Pd(II)_{0.08}-UiO-67-bpy. Pd(OAc)₂ (22.5 mg, 0.105 mmol) and UiO-67-bpy (213 mg, 0.1 mmol) were dispersed in 3 mL of acetone respectively. Then the Pd(II) solution was added to MOF solution dropwise. After stirring for 6 h at 30 °C, the brown solid Pd(II)_{0.08}-UiO-67-bpy was collected *via* centrifugation and washed with acetone (3×10 mL), followed by soaking in acetone for 3 d. The solution was exchanged with fresh acetone (10 mL) every 24 h and finally dried under vacuum at 80 °C for 12 h.

(3) Synthesis of Pd(II)_{0.09}-UiO-67-bpy. Similar conditions were involved except Pd(OAc)₂ (0.2 mmol, 45 mg) was used.

(4) Synthesis of Pd(II)_{0.15}-UiO-67-bpy. Similar conditions were involved except Pd(OAc)₂ (0.3 mmol, 67.5 mg) was used.

(5) Synthesis of Pd(II)_{0.25}-UiO-67-bpy. Similar conditions were involved except Pd(OAc)₂ (0.4 mmol, 90 mg) was used.

3. Characterization of Catalysts




Figure S1. SEM images and EDS mapping of catalysts. (a) UiO-67-bpy, (b) Pd(II)_{0.08}-UiO-67-bpy, (c) Pd(II)_{0.15}-UiO-67-bpy, (d) Pd(II)_{0.25}-UiO-67-bpy, (e) Pd(II)_{0.09}-UiO-67-bpy and corresponding element distribution of (f) O, (g) N, (h) Zr and (i) Pd.




Figure S2. PXRD of UiO-67-bpy and Pd(II)_x-UiO-67-bpy.




Figure S3. XPS spectra of Pd 3d for Pd(II)_x-UiO-67-bpy.




Figure S4. XPS spectra of N 1s for Pd(II)_x-UiO-67-bpy.




Figure S5. FI-IR images of catalysts. FI-IR images of Pd(II)_{0.08}-UiO-67-bpy, Pd(II)_{0.09}-UiO-67-bpy, Pd(II)_{0.15}-UiO-67-bpy and Pd(II)_{0.25}-UiO-67-bpy.




Figure S6. FI-IR images of Pd(II)_{0.09}-UiO-67-bpy before and after catalysis.




Figure S7. TGA images of catalysts. TGA images of Pd(II)_{0.08}-UiO-67-bpy, (II)_{0.09}-UiO-67-bpy, Pd(II)_{0.15}-UiO-67-bpy and Pd(II)_{0.25}-UiO-67-bpy.




Figure S8. TGA images of Pd(II)_{0.09}-UiO-67-bpy before and after catalysis.




Figure S9. BET images of Pd(II)_{0.09}-UiO-67-bpy before and after catalysis.




Figure S10. TEM image of (a) Pd(II)_{0.08}-UiO-67-bpy after catalysis and corresponding EDS mapping (b) O, (c) Zr, (d) N and (e) Pd.




Figure S11. TEM image of (a) Pd(II)_{0.25}-UiO-67-bpy after catalysis and corresponding EDS mapping (b) O, (c) Zr, (d) N and (e) Pd.




Figure S12. XPS profiles of catalysts. (a) Pd 3d level for Pd(II)_{0.08}-UiO-67-bpy, (b) N 1s level for Pd(II)_{0.08}-UiO-67-bpy, (c) Pd 3d level for Pd(II)_{0.25}-UiO-67-bpy, (d) N 1s level for Pd(II)_{0.25}-UiO-67-bpy.




Figure S13. (a) Pd 3d level and (b) N 1s level for Pd(II)_{0.09}-UiO-67-bpy after catalysis via path b.




Figure S14. PXRD spectral of Pd(II)_{0.09}-UiO-67-bpy after catalysis *via* path b.




Figure S15. TEM images of homogeneous system I and II after catalysis. (a) TEM image of Pd species in homogeneous I when the reaction proceeded for 40 min, (b) 60 min, (c) TEM image of Pd species in homogeneous II when the reaction proceeded for 60 min.





Figure S16. Reusability of Pd(II)_{0.09}-UiO-67-bpy

Table S1. Screening of the amount of Na₂CO₃

Reaction scheme: **1a** + **2a** $\xrightarrow{\text{catalyst}}$ **4a**


Entry	Base (equiv)	Yield (%)	TON
1	Na ₂ CO ₃ (1.0)	71	443
2	Na ₂ CO ₃ (0.5)	68	425
3	Na ₂ CO ₃ (0.3)	33	206
4	Na ₂ CO ₃ (0)	n.d.	n.d.

^aThe reaction conditions were: **1a** (0.1 mmol), **2a** (0.15 mmol), Pd(II)_{0.09}-UiO-67-bpy (Pd 0.16 mol %), dry DMSO (1 mL), air, 25 °C and 12 h. Yield of **4a** was determined by ¹H NMR using CH₂Br₂ as an internal standard. n.d. = not detected.

Table S2. Screening of the ratio of Pd(OAc)₂: bpy in Pd(II)_x-UiO-bpy.

Entry	Catalyst	Yield (%)	TON
1	Pd(II) _{0.08} -UiO-67-bpy (2 mg, Pd 0.07 mol %)	50	714
2	Pd(II) _{0.08} -UiO-67-bpy (4 mg, Pd 0.14 mol %)	51	364
3	Pd(II) _{0.08} -UiO-67-bpy (8 mg, Pd 0.28 mol %)	71	254
4	Pd(II) _{0.09} -UiO-67-bpy (2 mg, Pd 0.08 mol %)	60	750
5	Pd(II) _{0.09} -UiO-67-bpy (4 mg, Pd 0.16 mol %)	83	519
6	Pd(II) _{0.09} -UiO-67-bpy (8 mg, Pd 0.32 mol %)	76	238
7	Pd(II) _{0.15} -UiO-67-bpy (2 mg, Pd 0.14 mol %)	74	529
8	Pd(II) _{0.15} -UiO-67-bpy (4 mg, Pd 0.28 mol %)	48	174
9	Pd(II) _{0.15} -UiO-67-bpy (8 mg, Pd 0.56 mol %)	50	89
10	Pd(II) _{0.25} -UiO-67-bpy (2 mg, Pd 0.23 mol %)	78	339
11	Pd(II) _{0.25} -UiO-67-bpy (4 mg, Pd 0.46 mol %)	77	167
12	Pd(II) _{0.25} -UiO-67-bpy (8 mg, Pd 0.92 mol %)	78	85
13	Pd(OAc) ₂ (0.16 mol%)	n.d.	-
14	Pd(OAc) ₂ (10 mol%)	32	3.2


^aThe reaction conditions were: **1a** (0.1 mmol), **2a** (0.15 mmol), Li₂CO₃ (30 mol %), dry DMSO (1 mL), N₂, 100 °C and 1 h. Yield of **3a** was determined by ¹⁹F NMR using CF₃Ph as an internal standard. n.d. = not detected.



Scheme S1. Possible reaction mechanism of Pd(II)_{0.09}-UiO-67-bpy-catalyzed cyclization of isonitriles with *N*-acyl-*o*-alkynylanilines for 1*H*-indole-3-carboxamides.


4. Characterization Data for All Products

N-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(3-phenylquinolin-2-yl)acetamide (**3a**)²




Yellow solid (31 mg, 83%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 7.8 Hz, 1H), 7.76 (m, 1H), 7.65 (t, *J* = 16.1 Hz, 1H), 7.53 – 7.41 (m, 5H), 1.14 (s, 9H); ¹³C NMR (100 MHz, Chloroform-*d*) δ 158.1, 157.7, 146.1, 139.1, 137.8, 134.8, 130.3, 129.6, 129.0, 128.6, 128.3, 128.2, 127.5, 117.8, 114.9, 62.9, 27.4 ppm; ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -67.64.

N-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(6-fluoro-3-phenylquinolin-2-yl)acetamide (**3b**)²




Yellow solid (30 mg, 78%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.18 (s, 1H), 8.14 (dd, $J = 9.1, 5.3$ Hz, 1H), 7.59 – 7.44 (m, 7H), 1.16 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 162.9, 160.4, 157.9 (q, $J = 34.6$ Hz), 149.2 (d, $J = 2.8$ Hz), 143.2, 138.4, 138.3, 137.5, 135.7, 132.3, 132.2, 129.9, 129.1-129.0 (m), 128.8, 120.7 (d, $J = 25.9$ Hz), 117.8, 114.9, 110.7, 110.5, 63.0, 27.4 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.69, -110.85 (td, $J = 8.4, 5.3$ Hz).

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(3-phenyl-6-(trifluoromethyl)quinolin-2-yl)acetamide (3c)²**



Yellow solid (40 mg, 91%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.31 (s, 1H), 8.24 (d, $J = 9.5$ Hz, 2H), 7.95 (dd, $J = 8.8, 1.8$ Hz, 1H), 7.55 – 7.43 (m, 5H), 1.15 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 157.9 (q, $J = 34.9$ Hz), 151.8, 147.1, 139.8, 137.1, 136.3, 130.9, 129.9 (d, $J = 7.0$ Hz), 129.2, 129.1, 127.3, 126.0 (q, $J = 2.9$ Hz), 125.5 (q, $J = 4.4$ Hz), 117.7, 63.3, 27.4 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -62.58, -67.65.

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(6-methyl-3-phenylquinolin-2-yl)acetamide (3d)²**




Yellow solid (26 mg, 67%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.11 (s, 1H), 8.01

(d, $J = 8.6$ Hz, 1H), 7.66 (s, 1H), 7.60 (d, $J = 8.6$ Hz, 1H), 7.52 – 7.41 (m, 5H), 2.58 (s, 3H), 1.13 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 158.0 (d, $J = 34.6$ Hz), 148.9, 144.7, 138.4, 138.0, 134.7, 132.7, 130.0, 129.3, 129.0, 128.5, 128.4, 126.3, 117.8, 114.9, 62.9, 27.4, 21.8 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.67.


***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(6-methoxy-3-phenylquinolin-2-yl)acetamide**

(3e)²




White solid (22 mg, 54%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.09 (s, 1H), 8.00 (d, $J = 9.2$ Hz, 1H), 7.50 – 7.40 (m, 6H), 7.14 (d, $J = 2.7$ Hz, 1H), 3.95 (s, 3H), 1.13 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 159.1, 157.7 (q, $J = 34.6$ Hz), 147.3, 142.0, 137.9, 137.6, 134.9, 130.9, 129.8, 129.4, 128.9, 128.3, 123.1, 117.7, 114.8, 104.7, 62.7, 55.7, 27.2 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.67.

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(7-fluoro-3-phenylquinolin-2-yl)acetamide (3f)²**




Yellow solid (35 mg, 90%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 7.90 (dd, $J = 9.0, 5.9$ Hz, 1H), 7.75 (dd, $J = 9.8, 2.5$ Hz, 1H), 7.52 – 7.41 (m, 6H), 1.14 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 164.9, 162.4, 157.9 (d, $J = 34.9$ Hz), 150.7, 147.2 (d, $J = 13.0$ Hz), 139.0, 137.5, 134.2, 129.9, 129.6 (d, $J = 10.0$ Hz), 129.1, 128.6, 125.4, 118.9 (d, $J = 25.6$ Hz), 117.8, 114.9, 113.4 (d, $J = 20.7$ Hz), 63.1, 27.4 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.66, -107.96 (dd, $J = 13.9$ Hz).

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(7-methyl-3-phenylquinolin-2-yl)acetamide (3g)²**




Yellow solid (24 mg, 63%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.16 (s, 1H), 7.91 (s, 1H), 7.79 (d, $J = 8.3$ Hz, 1H), 7.52 – 7.41 (m, 6H), 2.60 (s, 3H), 1.14 (s, 9H); ¹³C NMR (100 MHz, Chloroform-*d*) δ 158.0 (d, $J = 34.7$ Hz), 149.6, 146.4, 140.9, 138.8, 138.0, 133.9, 130.5, 129.9, 129.0, 128.6, 128.4, 127.2, 126.4, 117.8, 115.0, 62.9, 27.4, 22.0 ppm; ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -67.65.

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(7-methoxy-3-phenylquinolin-2-yl)acetamide (3h)**




Yellow solid (25 mg, 63%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.13 (s, 1H), 7.77 (d, $J = 9.0$ Hz, 1H), 7.50 – 7.39 (m, 6H), 7.29 (dd, $J = 8.9, 2.5$ Hz, 1H), 3.99 (s, 3H), 1.14 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 161.6, 157.7, 149.8, 148.0, 138.9, 138.0, 132.4, 129.9, 129.0, 128.5, 128.3, 123.6, 121.7, 117.8, 115.0, 107.3, 62.9, 55.9, 27.4 ppm; ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -67.61. ν_{\max} (KBr)/cm⁻¹ 2935, 1695, 1621, 1492, 1374, 1029, 932, 758, 704, 480; HRMS-ESI (*m/z*): calcd for C₂₂H₂₂F₃N₂O₂, [M+H]⁺: 403.1628, found 403.1622.

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(3-(4-(trifluoromethyl)phenyl)quinolin-2-yl)acetamide (3i)²**




Yellow solid (35 mg, 80%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.23 (s, 1H), 8.14 (d, $J = 8.4$ Hz, 1H), 7.93 (d, $J = 8.2$ Hz, 1H), 7.80 (dd, $J = 20.8, 7.6$ Hz, 3H), 7.68 (t, $J = 8.0$ Hz, 1H), 7.59 (d, $J = 8.2$ Hz, 2H), 1.16 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 158.1 (d, $J = 34.7$ Hz), 149.2, 146.5, 141.6, 139.4, 133.3, 130.9, 130.3, 129.7, 128.6, 128.1, 127.6, 126.0 (q, $J = 37$ Hz), 120.9 (d, $J = 41.7$ Hz), 117.7, 114.9, 63.2, 27.5 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -62.66, -67.66.

***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(3-(*p*-tolyl)quinolin-2-yl)acetamide (3j)²**



Red solid (22 mg, 55%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 8.13 (d, $J = 8.4$ Hz, 1H), 7.91 (d, $J = 8.1$ Hz, 1H), 7.79 (t, $J = 7.0$ Hz, 1H), 7.66 (t, $J = 7.5$ Hz, 1H), 7.35 (q, 4H), 2.45 (s, 3H), 1.18 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 158.1 (q, $J = 34.5$ Hz), 149.8, 146.0, 138.9, 138.5, 134.9, 129.8, 129.7, 129.6, 128.4, 128.1, 127.5, 117.8, 114.9, 62.9, 27.4, 21.3 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.68.


***N*-(*tert*-Butyl)-2,2,2-trifluoro-*N*-(3-(4-methoxyphenyl)quinolin-2-yl)acetamide (3k)²**



Yellow solid (22 mg, 54%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.17 (s, 1H), 8.10 (d, $J = 8.5$ Hz, 1H), 7.88 (d, $J = 8.2$ Hz, 1H), 7.75 (t, $J = 7.2$ Hz, 1H), 7.62 (t, $J = 7.2$ Hz, 1H), 7.37 (d, $J = 6.7$ Hz, 2H), 7.02 (d, $J = 8.8$ Hz, 2H), 3.87 (s, 3H), 1.16 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 159.9, 158.0 (q, $J = 34.6$ Hz), 149.8, 145.9, 138.7,


134.5, 131.2, 130.1, 130.0, 129.6, 128.4, 128.1, 127.4, 117.8, 114.5, 62.9, 55.5, 27.4 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -67.67.

***N*-(*tert*-Butyl)-2,2,3,3,3-pentafluoro-*N*-(3-phenylquinolin-2-yl)propanamide (3l)²**




Yellow solid (25 mg, 58%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 8.11 (d, $J = 8.2$ Hz, 1H), 7.90 (d, $J = 7.4$ Hz, 1H), 7.78 (t, $J = 7.6$ Hz, 1H), 7.65 (t, $J = 7.6$ Hz, 1H), 7.52 – 7.43 (m, 5H), 1.14 (s, 9H); ^{13}C NMR (100 MHz, Chloroform-*d*) δ 159.1 (t, $J = 23.6$ Hz), 149.5, 146.1, 138.9, 137.9, 134.7, 130.3, 129.9, 129.7, 129.0, 128.5, 128.3, 128.2, 127.5, 119.9, 117.0, 63.3, 27.3 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -80.71, -111.99 (d, $J = 10.0$ Hz).

***N*-Cyclohexyl-2,2,2-trifluoro-*N*-(3-phenylquinolin-2-yl)acetamide (3m)²**




Yellow solid (14 mg, 35%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.21 (s, 1H), 8.10 (d, $J = 8.5$ Hz, 1H), 7.89 (d, $J = 8.1$ Hz, 1H), 7.77 (dd, $J = 7.7$ Hz, 1H), 7.63 (t, $J = 7.5$ Hz, 1H), 7.51-7.43 (m, 5H), 3.39-3.49 (m, 1H), 1.80-1.65 (m, 3H), 1.76-1.66 (m, 2H), 1.56 (t, 2H), 1.45-1.36 (m, 2H), 1.08-0.83 (m, 4H); ^{13}C NMR (101 MHz, Chloroform-*d*) δ 158.55 (q, $J = 35.5$ Hz), 150.5, 146.1, 139.8, 137.3, 130.0, 129.5, 129.4, 129.0, 128.7, 128.1, 128.0, 127.5, 117.8, 114.9, 63.8, 29.0, 28.2, 26.3, 26.0, 25.3 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -68.18.

***N*-(Adamantan-1-yl)-2,2,2-trifluoro-*N*-(3-phenylquinolin-2-yl)acetamide (3n)²**




Yellow solid (25 mg, 56%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.19 (s, 1H), 8.15 (d, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 8.1 Hz, 1H), 7.81-7.76 (m, 1H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.52-7.41 (m, 5H), 2.02 (d, *J* = 11.5 Hz, 3H), 1.88 (s, 3H), 1.61 (d, *J* = 11.5 Hz, 3H), 1.49-1.41 (m, 6H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 157.37 (q, *J* = 34.5 Hz), 149.1, 145.9, 138.9, 137.9, 135.2, 129.6, 128.9, 128.6, 128.2, 127.5, 117.7, 114.8, 64.7, 38.6, 30.1 ppm; ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -67.65.

2,2,2-Trifluoro-*N*-(3-Phenylquinolin-2-yl)-*N*-(2,4,4-trimethylpentan-2-yl)acetamide (3o)²




Yellow solid (28 mg, 65%); ¹H NMR (400 MHz, Chloroform-*d*) δ 8.19 (s, 1H), 8.13 (d, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.78 (t, *J* = 7.7 Hz, 1H), 7.65 (t, *J* = 8.0 Hz, 1H), 7.52-7.39 (m, 5H), 2.36 (d, *J* = 14.6 Hz, 1H), 1.27 (s, 4H), 0.93 (s, 3H), 0.90 (s, 9H); ¹³C NMR (101 MHz, Chloroform-*d*) δ 157.6 (q, *J* = 34.5 Hz), 149.7, 146.1, 139.1, 137.9, 135.2, 130.3, 130.1, 129.6, 129.0, 128.5, 128.2, 128.2, 127.5, 117.9, 114.9, 67.9, 49.9, 31.7, 31.5, 27.5, 27.0 ppm; ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -67.51.

***N*-Cyclopentyl-2,2,2-trifluoro-*N*-(3-phenylquinolin-2-yl)acetamide (3p)²**




Yellow solid (14 mg, 37%); ^1H NMR (400 MHz, Chloroform-*d*) δ 8.23 (s, 1H), 8.10 (d, $J = 8.5$ Hz, 1H), 7.90 (d, $J = 8.1$ Hz, 1H), 7.78 (t, $J = 7.5$ Hz, 1H), 7.64 (t, $J = 7.5$ Hz, 1H), 7.48-7.43 (m, 5H), 3.87 (p, $J = 8.3$ Hz, 1H), 1.70-1.50 (m, 8H); ^{13}C NMR (101 MHz, Chloroform-*d*) δ 150.5, 139.7, 130.5, 129.4, 129.1, 128.6, 128.1, 127.6, 64.1, 24.6, 24.2 ppm; ^{19}F NMR (376 MHz, Chloroform-*d*) δ -68.27; ν_{max} (KBr)/ cm^{-1} 2956, 1699, 1584, 1487, 1410, 1371, 1186, 760, 701, 595, 482. $[\text{M}+\text{H}]^+$: 385.1522, found 385.1518.

***N*-tert-Butyl-2-phenyl-1*H*-indole-3-carboxamide (4a)³**



White solid (19 mg, 65%); ^1H NMR (400 MHz, DMSO-*d*₆) δ 11.64 (s, 1H), 7.73-7.69 (m, 3H), 7.52-7.48 (m, 2H), 7.43-7.40 (m, 2H), 7.19-7.13 (m, 1H), 7.12-7.06 (m, 2H), 1.32 (s, 9H); ^{13}C NMR (101 MHz, DMSO-*d*₆) δ 165.1, 135.4, 128.5, 128.3, 128.3, 122.1, 120.0, 119.9, 111.4, 50.4, 28.6 ppm.


***N*-tert-Butyl-2-phenyl-5-trifluoromethyl-1*H*-indole-3-carboxamide (4b)³**



White solid (18 mg, 52%); ^1H NMR (400 MHz, DMSO-*d*₆) δ 12.12 (s, 1H), 8.04 (s, 1H), 7.74 (d, $J = 8.5$ Hz, 2H), 7.60 (d, $J = 8.5$ Hz, 1H), 7.54 (t, $J = 7.4$ Hz, 2H), 7.47 (t, $J = 7.3$ Hz, 2H), 1.30 (s, 9H); ^{13}C NMR (101 MHz, DMSO-*d*₆) δ 164.3, 139.2, 136.9,


131.1, 128.9, 128.6, 126.8, 118.5, 117.3, 112.3, 111.4, 50.5, 39.5, 28.5 ppm.

***N*-tert-Butyl-5-methyl-2-phenyl-1*H*-indole-3-carboxamide (4c)³**




White solid (21 mg, 68%); ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.51 (s, 1H), 7.71-7.69 (m, 2H), 7.51-7.45 (m, 3H), 7.43-7.39 (m, 1H), 7.42 (m, 1H), 7.29 (d, *J* = 8.2 Hz, 1H), 7.02-6.93 (m, 2H), 2.40 (s, 3H), 1.31 (s, 9H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 165.1, 136.7, 133.8, 131.9, 128.4, 128.3, 128.2, 127.7, 123.7, 119.5, 111.1, 110.5, 50.3, 21.4 ppm.

***N*-tert-Butyl-2-(4-trifluoromethyl)-1*H*-indole-3-carboxamide (4d)**




White solid (12 mg, 32%); ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.82 (s, 1H), 7.94 (d, *J* = 8.2 Hz, 2H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.52 (s, 1H), 7.45 (d, *J* = 8.1 Hz, 1H), 7.20 (t, *J* = 8.0 Hz, 1H), 7.12 (t, *J* = 7.8 Hz, 1H), 1.36 (s, 9H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 164.9, 135.9, 135.7, 134.5, 128.6, 127.1, 122.8, 120.3, 119.9, 112.8, 111.6, 50.6, 28.5 ppm; ν_{\max} (KBr)/cm⁻¹ 3700, 3011, 1590, 1518, 1446, 1322, 1168, 1113, 1064, 747, 471; HRMS-ESI (*m/z*): calcd for C₂₀H₁₉F₃N₂O₁, [M+H]⁺: 361.1517, found 361.1522.

***N*-tert-Butyl-2-*p*-tolyl-1*H*-indole-3-carboxamide (4e)³**




White solid (8 mg, 26%); ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.57 (s, 1H), 7.69 (d, $J = 7.8$ Hz, 1H), 7.62 (d, $J = 8.0$ Hz, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.14 (t, $J = 7.5$ Hz, 1H), 7.07 (s, 1H), 7.06 (s, 1H), 2.37 (s, 3H), 1.32 (s, 9H); ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 165.1, 137.7, 136.8, 135.3, 129.0, 128.2, 127.4, 121.9, 119.9, 119.7, 111.3, 50.3, 39.5, 28.6, 20.9 ppm.

***N*-tert-Butyl-2-(4-methoxyphenyl)-1*H*-indole-3-carboxamide (4f)³**



White solid (24 mg, 74%); ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.53 (s, 1H), 7.71 (d, $J = 7.8$ Hz, 1H), 7.67 (d, $J = 8.8$ Hz, 2H), 7.38 (d, $J = 7.9$ Hz, 1H), 7.13 (t, $J = 7.5$ Hz, 1H), 7.07 (d, $J = 8.8$ Hz, 3H), 6.97 (s, 1H), 3.82 (s, 3H), 1.32 (s, 9H); ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 165.1, 159.4, 136.9, 135.2, 129.7, 127.5, 124.1, 119.9, 119.7, 111.2, 110.0, 55.3, 50.3, 39.5, 28.6 ppm.

***N*-(2,4,4-Trimethylpentan-2-yl)-2-phenyl-1*H*-indole-3-carboxamide (4g)**




White solid (26 mg, 75%); ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.64 (s, 1H), 7.77 (d, $J = 7.8$ Hz, 1H), 7.72 (d, $J = 7.3$ Hz, 2H), 7.51 (t, $J = 7.5$ Hz, 2H), 7.44 (d, $J = 7.4$ Hz, 1H), 7.40 (d, $J = 8.1$ Hz, 1H), 7.15 (t, $J = 7.0$ Hz, 1H), 7.08 (t, $J = 7.4$ Hz, 1H), 6.78 (s, 1H), 1.75 (s, 2H), 1.33 (s, 6H), 0.90 (s, 9H); ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 164.8, 135.4, 131.9, 128.7, 128.4, 122.0, 120.0, 111.3, 111.0, 54.2, 50.9, 39.5, 31.2, 28.9 ppm; $\nu_{\text{max}}(\text{KBr})/\text{cm}^{-1}$ 3698, 2956, 1723, 1629, 1514, 1450, 1222, 1002, 743, 695, 640, 487, HRMS-ESI (m/z): calcd for $\text{C}_{23}\text{H}_{29}\text{N}_2\text{O}_1$, $[\text{M}+\text{H}]^+$: 349.2269, found 349.2274.

5. Reference


1. X. Li, R. Van Zeeland, R. V. Maligal-Ganesh, Y. Pei, G. Power, L. Stanley and W. Huang, *ACS Catal.*, 2016, **6**, 6324.
2. M. Li, J. Zheng, W. Hu, C. Li, J. Li, S. Fang, H. Jiang and W. Wu, *Org. Lett.*, 2018, **20**, 7245.
3. Z. Hu, D. Liang, J. Zhao, J. Huang and Q. Zhu, *Chem. Commun.*, 2012, **48**, 7371.

6. Copies of ^1H , ^{13}C and ^{19}F NMR Spectra


^1H NMR of **3a**




^{13}C NMR of **3a**




¹⁹F NMR of **3a**




¹H NMR of **3b**




¹³C NMR of **3b**




¹⁹F NMR of **3b**




¹H NMR of 3c




¹³C NMR of 3c




¹⁹F NMR of **3c**




¹H NMR of 3d




¹³C NMR of 3d




¹⁹F NMR of **3d**




¹H NMR of 3e




¹³C NMR of 3e




¹⁹F NMR of **3e**




¹H NMR of 3f




¹³C NMR of 3f




¹⁹F NMR of **3f**




¹H NMR of **3g**




¹³C NMR of **3g**




^{19}F NMR of **3g**




¹H NMR of 3h




¹³C NMR of 3h




¹⁹F NMR of **3h**




¹H NMR of **3i**




¹³C NMR of **3i**




¹⁹F NMR of **3i**




¹H NMR of **3j**




¹³C NMR of **3j**




¹⁹F NMR of **3j**




¹H NMR of **3k**




¹³C NMR of **3k**




¹⁹F NMR of **3k**




¹H NMR of 3I




¹³C NMR of 3I




¹⁹F NMR of **31**




¹H NMR of 3m




¹³C NMR of 3m




¹⁹F NMR of **3m**




¹H NMR of 3n




¹³C NMR of 3n




^{19}F NMR of **3n**




¹H NMR of **3o**




¹³C NMR of **3o**




¹⁹F NMR of **3o**




¹H NMR of 3p




¹³C NMR of 3p




¹⁹F NMR of **3p**




^1H NMR of **4a**




^{13}C NMR of **4a**




^1H NMR of **4b**




^{13}C NMR of **4b**




^1H NMR of **4c**




^{13}C NMR of **4c**




¹H NMR of 4d




¹³C NMR of 4d




¹H NMR of 4e




¹³C NMR of 4e




^1H NMR of **4f**



^{13}C NMR of **4f**



¹H NMR of 4g



¹³C NMR of 4g

